Cafepharma Today

May 14 2025 - AbbVie pays ADARx $335M cash for next-gen siRNA options
AbbVie pays ADARx $335M cash for next-gen siRNA options
Novo Nordisk inks $2.2B deal for Septerna's preclinical obesity programs
Roche reports final overall survival outcomes from breast cancer treatment trial
GSK buys phase III–ready liver drug in potential $2B deal to play in MASH arena
*please scroll down for all the latest news *

Make it like cafepharma, but for different industries. Learn more about CompanyUnderground

Check open job listings in your area
Click here to stay updated on CP happenings

learn about pharmaceutical fraud
learn about the False Claims Act
learn about clinical lab fraud

Current News

submit a press release

Medicare spending on diabetes drugs surged in 5 years
Axios
Tuesday, February 25, 2025 - 10:53am
tags:
Medicare, diabetes, GLP-1 agonists
Lava, smoldering from dropping lead asset, lays off 30% of staff to save cash
Fierce Biotech
Tuesday, February 25, 2025 - 10:52am
tags:
Lava Therapeutics, blood cancer, LAVA-1266, layoffs
Repare unveils scale of layoffs with 75% of staff and chief medical officer heading for exit
Fierce Biotech
Tuesday, February 25, 2025 - 10:49am
tags:
Repare Therapeutics, layoffs
Incentivizing rare disease R&D is getting tougher, but revamped policies could turn the tide
Pharma Voice
Tuesday, February 25, 2025 - 10:47am
tags:
R&D, Rare Diseases, artificial intelligence
FDA brings back some fired device office staff
BioPharma Dive
Tuesday, February 25, 2025 - 10:45am
tags:
FDA, Medtech, devices, HHS
Pharma's AI is missing the "Why”
Pharmaphorum
Tuesday, February 25, 2025 - 10:43am
tags:
artificial intelligence, clinical trials, drug discovery
“Digital genocide”: BMJ post alleges patient data deletion amid DEI purge
Clinical Trials Arena
Tuesday, February 25, 2025 - 10:42am
tags:
BMJ, diversity, Donald Trump
In letter to RFK Jr., Democrats flag threats to drug review process from FDA firings
Fierce Pharma
Monday, February 24, 2025 - 5:07pm
tags:
FDA, drug reviews, HHS, Robert F Kennedy Jr.
Regeneron's gene therapy study shows improved hearing in children with congenital deafness
Contemporary Pediatrics
Monday, February 24, 2025 - 5:05pm
tags:
Regeneron, gene therapy, DB-OTO, genetic hearing loss, genetic deafness
Anne Wojcicki has a new offer to take 23andMe private, this time for $74.7 million
CNBC
Monday, February 24, 2025 - 4:58pm
tags:
23andMe, Anne Wojcicki
Trump administration, pharma clash: 4 notes
Beckers Hospital Review
Monday, February 24, 2025 - 4:54pm
tags:
Donald Trump, tariffs, Eli Lilly, Merck, Pfizer, PhRMA
Pfizer names Patrizia Cavazzoni, former top FDA official, as chief medical officer
BioPharma Dive
Monday, February 24, 2025 - 4:52pm
tags:
Pfizer, FDA, Patrizia Cavazzoni
Sanofi shows how $500M bowel disease bet compares to Merck and Roche's rival assets
Fierce Biotech
Monday, February 24, 2025 - 11:32am
tags:
Sanofi, Teva Pharmaceutical, Merck, Roche, clinical trials, duvakitug, IBD, inflammatory bowel disease
FDA approves Medtronic’s adaptive deep-brain stimulator for Parkinson’s disease
Fierce Biotech
Monday, February 24, 2025 - 11:30am
tags:
Medtronic, Medtech, FDA, neurostimulation, Parkinson's Disease, BrainSense
Following their flashy Super Bowl ad buys, healthcare and pharma players face pushback
Medical Marketing and Media
Monday, February 24, 2025 - 11:19am
tags:
pharma advertising, Super Bowl
VitalConnect raises $100M for heart monitor patch
Medtech Dive
Monday, February 24, 2025 - 11:17am
tags:
VitalConnect, Medtech, heart monitor patch, arrhythmia, Vitalpatch, funding
FDA Clears Entrada Therapeutics' Early-Stage For Potential Treatment Of Duchenne Muscular Dystrophy
Benzinga
Monday, February 24, 2025 - 11:15am
tags:
Entrada Therapeutics, ENTR-601-44, DMD, Duchenne Muscular Dystrophy, FDA
Pfizer inks deal to test Summit’s white-hot bispecific with ADCs
Fierce Biotech
Monday, February 24, 2025 - 11:11am
tags:
Pfizer, Summit Therapeutics, ivonescimab, antibody-drug conjugates
Eli Lilly, Novo Nordisk lead revenue boom in the 'always tricky' Q4
Fierce Pharma
Monday, February 24, 2025 - 11:09am
tags:
earnings, Big Pharma, Eli Lilly, Novo Nordisk
OSE’s UC therapy prompts 16% clinical remission after ten weeks
Clinical Trials Arena
Monday, February 24, 2025 - 10:17am
tags:
OSE Therapeutics, lusvertikimab, clinical trials, ulcerative colitis

Pages

Latest CP Wire Articles

Hermes Intelligence Launches to Redefine Pharma Data Solutions [sponsored]
The Evolution of Medical Sales: What’s Changing in 2025?
FDA Scraps Key Vaccine Meetings—What It Means for Manufacturers
FDA approves Danziten, the first nilotinib treatment for Ph+ CML with no mealtime restrictions
Daily U.S. Flu Cases Expected to Nearly Double from Last Year by Late November, Predicts Novel Mathematical Forecasting Tool
PharmaBlock Receives 2024 ACS CMO Excellence in Green Chemistry Award, Marking a Second Consecutive Year of Recognition
Leading Clinical Research Network Centricity Research Acquires North Carolina-based Lucas Research
First-of-Its-Kind Alzheimer’s Disease Simulation Paves Way for Personalized Treatment: Penn State, Duke University Study
Centricity Research Appoints New CEO, CFO to Support Next Phase of Growth
Sermo Barometer Examines Influencers’ Impact on Patient Perceptions of Weight Loss Medications & Preventative Care Technologies

Latest Pharmagather Articles

New Cell Therapy For Resistant Hodgkins Patients
In the Pipeline
Escape From the Lysosome
In the Pipeline
Heavy Water in Your NMR Experiments, And Elsewhere
In the Pipeline
GIPR: Agonists and Antagonists Do the Same Thing, But How
In the Pipeline
Mutant Proteins Classified
In the Pipeline
The Continuing Crisis, Part XIV: The Trumpist Worldview
In the Pipeline
Whole Lotta Snakin' Going On
In the Pipeline
The GLP-1 Saga Continues, And How
In the Pipeline
Defluorination is Happening Inside You Right Now
In the Pipeline

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.